Activation of TLR2 by a small molecule produced by Staphylococcus epidermidis increases antimicrobial defense against bacterial skin infections.
Production of antimicrobial peptides by epithelia is an essential defense against infectious pathogens. In this study we evaluated whether the commensal microorganism Staphylococcus epidermidis may enhance production of antimicrobial peptides by keratinocytes and thus augment skin defense against infection. Exposure of cultured undifferentiated human keratinocytes to a sterile nontoxic small molecule of <10 kDa from S. epidermidis conditioned culture medium (SECM), but not similar preparations from other bacteria, enhanced human beta-defensin 2 (hBD2) and hBD3 mRNA expression and increased the capacity of cell lysates to inhibit the growth of group A Streptococcus (GAS) and S. aureus. Partial gene silencing of hBD3 inhibited this antimicrobial action. This effect was relevant in vivo as administration of SECM to mice decreased susceptibility to infection by GAS. Toll-like receptor 2 (TLR2) was important to this process as a TLR2-neutralizing antibody blocked induction of hBDs 2 and 3, and Tlr2-deficient mice did not show induction of mBD4. Taken together, these findings reveal a potential use for normal commensal bacterium S. epidermidis to activate TLR2 signaling and induce antimicrobial peptide expression, thus enabling the skin to mount an enhanced response to pathogens.
Lai
Yuping
Y
Division of Dermatology, Department of Medicine, University of California, San Diego and VA San Diego Healthcare System, San Diego, California 92161, USA.
Cogen
Anna L
AL
Radek
Katherine A
KA
Park
Hyun Jeong
HJ
Macleod
Daniel T
DT
Leichtle
Anke
A
Ryan
Allen F
AF
Di Nardo
Anna
A
Gallo
Richard L
RL
D000818:Animals; D057134:Antibodies, Neutralizing / Q000276:immunology; D001426:Bacterial Proteins / Q000378:metabolism*; D002478:Cells, Cultured; D017077:Culture Media, Conditioned / Q000494:pharmacology; D000078404:Epidermal Cells; D004817:Epidermis / Q000276:immunology / Q000382:microbiology; D020868:Gene Silencing; D006801:Humans; D015603:Keratinocytes / Q000166:cytology / Q000382:microbiology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D015398:Signal Transduction / Q000276:immunology; D013207:Staphylococcal Skin Infections / Q000276:immunology / Q000378:metabolism / Q000517:prevention & control*; D013211:Staphylococcus aureus; D013212:Staphylococcus epidermidis; D013290:Streptococcal Infections / Q000276:immunology / Q000378:metabolism / Q000517:prevention & control; D013297:Streptococcus pyogenes; D051195:Toll-Like Receptor 2 / Q000276:immunology / Q000378:metabolism*; D023083:beta-Defensins / Q000235:genetics / Q000378:metabolism
D057134:Antibodies, Neutralizing; D001426:Bacterial Proteins; D017077:Culture Media, Conditioned; C422950:DEFB103A protein, human; C106641:DEFB4A protein, human; C495342:TLR2 protein, human; C493486:Tlr2 protein, mouse; D051195:Toll-Like Receptor 2; D023083:beta-Defensins
Br J Dermatol. 1969;81:Suppl 1:2-13
4904211
Annu Rev Immunol. 2003;21:335-76
12524386
Clin Immunol. 2006 Dec;121(3):332-8
17015038
J Invest Dermatol. 2008 Apr;128(4):816-24
17943182
N Engl J Med. 1997 Sep 18;337(12):816-21
9295241
Inflamm Bowel Dis. 2003 Jul;9(4):215-23
12902844
J Biol Chem. 2003 May 2;278(18):15587-94
12594207
Nat Immunol. 2002 Sep;3(9):875-81
12154357
J Clin Invest. 2007 Mar;117(3):803-11
17290304
Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2927-32
17293459
Infect Immun. 2000 May;68(5):2907-15
10768988
Immunol Rev. 2000 Feb;173:5-16
10719663
Can J Microbiol. 1983 Jun;29(6):700-3
6411317
J Invest Dermatol. 1996 Apr;106(4):701-10
8618008
Nat Immunol. 2003 Mar;4(3):269-73
12548285
FEMS Microbiol Lett. 2009 Jan;290(2):149-55
19054079
Trends Immunol. 2009 Mar;30(3):131-41
19217824
Clin Rev Allergy Immunol. 2007 Oct;33(1-2):15-26
17992585
Proc Natl Acad Sci U S A. 2007 May 29;104(22):9469-74
17517597
Am J Respir Cell Mol Biol. 2000 Jun;22(6):714-21
10837369
Curr Top Microbiol Immunol. 2006;306:91-110
16909919
J Invest Dermatol. 2007 Oct;127(10):2368-80
17460726
Br J Dermatol. 2003 Nov;149 Suppl 66:2-4
14616336
Nature. 1997 Jun 26;387(6636):861
9202117
Nat Rev Immunol. 2001 Nov;1(2):135-45
11905821
Infect Disord Drug Targets. 2008 Sep;8(3):144-55
18782031
Br J Dermatol. 2007 Dec;157 Suppl 2:1-7
18067623
J Exp Med. 2001 May 7;193(9):1067-76
11342591
J Invest Dermatol. 2005 Jul;125(1):9-13
15982297
Chem Immunol Allergy. 2005;86:22-41
15976486
J Allergy Clin Immunol. 2008 Oct;122(4):829-831
19014773
J Immunol. 2004 Sep 1;173(5):2909-12
15322146
Front Biosci. 2004 Jan 01;9:841-63
14766414
Infect Immun. 2005 Oct;73(10):6771-81
16177355
J Invest Dermatol. 2002 Feb;118(2):275-81
11841544
Nat Med. 2009 Dec;15(12):1377-82
19966777
Nat Immunol. 2005 Jun;6(6):551-7
15908936
Trends Immunol. 2003 Jul;24(7):358-63
12860525
FASEB J. 2008 Jul;22(7):2168-76
18263703
FASEB J. 2005 Jul;19(9):1067-77
15985530
Pharm Res. 1992 May;9(5):663-9
1608900
Cell. 2004 Jul 23;118(2):229-41
15260992
Clin Diagn Lab Immunol. 2003 Jan;10(1):161-6
12522054
J Med Microbiol. 2007 Dec;56(Pt 12):1675-1683
18033838
J Invest Dermatol. 1950 Oct;15(4):305-24
14779047
J Dermatol Sci. 2009 Apr;54(1):1-5
19203862
Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20858-63
19075245
Science. 2006 Mar 24;311(5768):1770-3
16497887
Mol Microbiol. 2007 Jan;63(2):497-506
17176256
Microbes Infect. 2006 May;8(6):1513-21
16697678
Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17994-9
19004758
J Invest Dermatol. 2010 Jan;130(1):192-200
19710683
Nature. 2001 Nov 22;414(6862):454-7
11719807
Science. 2006 Aug 25;313(5790):1126-30
16931762
Exp Dermatol. 2000 Jun;9(3):165-9
10839713
Nat Biotechnol. 2004 Feb;22(2):192-7
14704682
Trends Microbiol. 2004 Mar;12(3):129-34
15001189
Genome Res. 2008 Jul;18(7):1043-50
18502944